Literature DB >> 25697898

IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis.

Özlem Sağlam1, Zehra Seda Ünal, Cansu Subaşı, Engin Ulukaya, Erdal Karaöz.   

Abstract

Tumor microenvironment is an important factor, which sustains and promotes the tumors by inflammatory signals. Interleukin-6 (IL-6) is known as a multifunctional cytokine, which is a major activator of the signaling pathway of Janus kinases (JAKs)/signal transducer and activator of transcription 3 (STAT3). In this study, we aimed to investigate the effect of IL-6 in the tumor microenvironment on carcinogenesis. For this purpose, healthy breast tissue-derived stromal cells (HBT-SCs) and malign breast tissue-derived stromal cells (MBT-SCs) were co-cultured with MCF-7 (human breast adenocarcinoma cell line) cells using semipermeable membranes. The cell proliferation was monitored with water-soluble tetrazolium (WST) and carboxyfluorescein succinimidyl ester (CFSE) assays. Protein levels were measured by enzyme-linked immunosorbent assay (ELISA) and Western blot hybridization, while gene expressions were measured by real-time PCR. The results demonstrated that IL-6 protein levels increased significantly in the supernatants of MBT-SCs when they were co-cultured with MCF-7 cells. In accordance with this, the expression of IL-6 was significantly higher in MBT-SCs. Additionally, the expression of STAT3 in MCF-7 cells increased slightly when they were co-cultured with MBT-SCs. Considering together, there is an important interaction between tumor microenvironment and tumor cells mediated by IL-6 signaling. Thereby, the targeting on IL-6 signaling in the treatment of cancer might effectively prevent the tumor progression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25697898     DOI: 10.1007/s13277-015-3241-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

Review 1.  The role of the microenvironment in mammary gland development and cancer.

Authors:  Kornelia Polyak; Raghu Kalluri
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-30       Impact factor: 10.005

Review 2.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

3.  Prospective dual role of mesenchymal stem cells in breast tumor microenvironment.

Authors:  Christiane Senst; Timo Nazari-Shafti; Stefan Kruger; Kirstin Höner Zu Bentrup; Charles L Dupin; Abigail E Chaffin; Sudesh K Srivastav; Philipp M Wörner; Asim B Abdel-Mageed; Eckhard U Alt; Reza Izadpanah
Journal:  Breast Cancer Res Treat       Date:  2012-11-10       Impact factor: 4.872

4.  Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments.

Authors:  A Kate Sasser; Bethany L Mundy; Kristen M Smith; Adam W Studebaker; Amy E Axel; Amanda M Haidet; Soledad A Fernandez; Brett M Hall
Journal:  Cancer Lett       Date:  2007-04-27       Impact factor: 8.679

Review 5.  Molecular characterisation of the tumour microenvironment in breast cancer.

Authors:  Min Hu; Kornelia Polyak
Journal:  Eur J Cancer       Date:  2008-11-19       Impact factor: 9.162

Review 6.  The microenvironment in breast cancer progression: biology and implications for treatment.

Authors:  Andrew E Place; Sung Jin Huh; Kornelia Polyak
Journal:  Breast Cancer Res       Date:  2011-11-01       Impact factor: 6.466

7.  Active roles of tumor stroma in breast cancer metastasis.

Authors:  Zahraa I Khamis; Ziad J Sahab; Qing-Xiang Amy Sang
Journal:  Int J Breast Cancer       Date:  2012-02-19

8.  Breast cancer biology: the multifaceted roles of mesenchymal stem cells.

Authors:  Shyam A Patel; Andrew C Heinrich; Bobby Y Reddy; Balaji Srinivas; Nicole Heidaran; Pranela Rameshwar
Journal:  J Oncol       Date:  2008-12-21       Impact factor: 4.375

9.  Gene expression profiling of the tumor microenvironment during breast cancer progression.

Authors:  Xiao-Jun Ma; Sonika Dahiya; Elizabeth Richardson; Mark Erlander; Dennis C Sgroi
Journal:  Breast Cancer Res       Date:  2009-02-02       Impact factor: 6.466

Review 10.  Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions.

Authors:  A Ben-Baruch
Journal:  Breast Cancer Res       Date:  2002-10-28       Impact factor: 6.466

View more
  6 in total

Review 1.  Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.

Authors:  Pritish Nilendu; Sachin C Sarode; Devashree Jahagirdar; Ishita Tandon; Shankargouda Patil; Gargi S Sarode; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cell Oncol (Dordr)       Date:  2018-07-19       Impact factor: 6.730

2.  Resveratrol reduces IL-6 and VEGF secretion from co-cultured A549 lung cancer cells and adipose-derived mesenchymal stem cells.

Authors:  Erhan Sahin; Cengiz Baycu; Ayse Tansu Koparal; Dilek Burukoglu Donmez; Ezgi Bektur
Journal:  Tumour Biol       Date:  2015-12-18

3.  Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.

Authors:  Nuo Ji; Ji-Wei Yu; Xiao-Chun Ni; Ju-Gang Wu; Shou-Lian Wang; Bo-Jian Jiang
Journal:  Tumour Biol       Date:  2016-09-12

Review 4.  The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation.

Authors:  Drenka Trivanović; Jelena Krstić; Ivana Okić Djordjević; Slavko Mojsilović; Juan Francisco Santibanez; Diana Bugarski; Aleksandra Jauković
Journal:  Mediators Inflamm       Date:  2016-08-18       Impact factor: 4.711

5.  Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.

Authors:  Xuan Sun; Jie Zhang; Zhiyong Wang; Wei Ji; Ran Tian; Fei Zhang; Ruifang Niu
Journal:  Int J Mol Sci       Date:  2017-02-13       Impact factor: 5.923

6.  The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.

Authors:  Beata Kotowicz; Malgorzata Fuksiewicz; Joanna Jonska-Gmyrek; Mariusz Bidzinski; Maria Kowalska
Journal:  Tumour Biol       Date:  2015-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.